Bank Of New York Mellon Corp Neoleukin Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.4 - $0.55 $5,748 - $7,904	14,372 New	14,372 $7,000
Q3 2022 Nov 14, 2022	SELL	$0.69 - $1.33 $58 - $113	-85 Reduced 0.59%	14,372 $9,000
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.25 $93,443 - $228,530	-101,569 Reduced 87.54%	14,457 $15,000
Q1 2022 May 11, 2022	SELL	$1.72 - $5.23 $3,656 - $11,118	-2,126 Reduced 1.8%	116,026 $218,000
Q4 2021 Feb 11, 2022	SELL	$4.65 - $7.75 $21,455 - $35,758	-4,614 Reduced 3.76%	118,152 $570,000
Q3 2021 Nov 12, 2021	BUY	$6.05 - $9.66 $46,125 - $73,647	7,624 Added 6.62%	122,766 $887,000
Q2 2021 Aug 11, 2021	SELL	$9.23 - $13.12 $5,584 - $7,937	-605 Reduced 0.52%	115,142 $1.06 Million
Q1 2021 May 13, 2021	SELL	$11.26 - $15.78 $39,725 - $55,671	-3,528 Reduced 2.96%	115,747 $1.42 Million
Q4 2020 Feb 09, 2021	BUY	$10.17 - $14.56 $80,627 - $115,431	7,928 Added 7.12%	119,275 $1.68 Million
Q3 2020 Nov 12, 2020	SELL	$9.68 - $17.01 $59,532 - $104,611	-6,150 Reduced 5.23%	111,347 $1.34 Million
Q2 2020 Aug 12, 2020	BUY	$9.95 - $17.05 $942,483 - $1.62 Million	94,722 Added 415.9%	117,497 $1.95 Million
Q1 2020 May 06, 2020	BUY	$6.12 - $13.64 $42,283 - $94,238	6,909 Added 43.55%	22,775 $259,000
Q4 2019 Feb 14, 2020	SELL	$2.65 - $12.72 $1,621 - $7,784	-612 Reduced 3.71%	15,866 $195,000
Q3 2019 Nov 07, 2019	BUY	$2.33 - $3.76 $38,393 - $61,957	16,478 New	16,478 $46,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.